Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas

Mycosis fungoides (MF) is the most prevalent subtype of primary cutaneous T-cell lymphomas (CTCLs). Sezary syndrome (SS) is another entity defined by leukaemic involvement, lymphadenopathy and erythroderma. Pegylated liposomal doxorubicin (PEG-DOXO) is an anthracycline used in the management of advanced primary CTCL, particularly in induction strategies. However, there are limited data on its effectiveness and tolerability in real-life patients. We report 36 patients who received PEG-DOXO for MF or SS in our centre, describing the patients' characteristics, response rates and tolerance to the treatment. The best overall responses were observed for the skin, with lower response rates for nodal involvement and moderate responses for blood disease. The treatment was mainly well tolerated, without severe adverse events, and no cardiotoxicity was observed on cardiac function monitoring.

Automated summary

This study reported 36 patients who received PEG-DOXO for MF or SS, showing the best overall responses for skin, lower response rates for nodal involvement, and moderate responses for blood disease. The treatment was well tolerated without severe adverse events, and no cardiotoxicity was observed on cardiac function monitoring.